Comparative Bioavailability of Intranasal Epinephrine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-22

Study Completion Date

2024-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Study to Compare the Bioavailability of Epinephrine following a Single Nasal Dose of FMXIN002 Microspheres Powder 3.6 mg, and 4mg with EpiPen 0.3mg Intramuscular Injection in Healthy Adults

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioavailability of Nasal Epinephrine

NCT04696822

Anaphylaxis

COMPLETED PHASE1

Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis

NCT07228325

Anaphylaxis Allergy

ENROLLING_BY_INVITATION PHASE1/PHASE2

FMXIN002 in Patients at Risk of Anaphylaxis

NCT07045701

Anaphylaxis Food

ENROLLING_BY_INVITATION PHASE2/PHASE3

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges

NCT06445374

Hypersensitivity Anaphylaxis

COMPLETED PHASE1

Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis (P08648)

NCT00564421

Seasonal Allergic Rhinitis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An open-label trial in 12 healthy adults. FMXIN002 (3.6 mg and 4.0 mg) will be administered intranasally to healthy adults and compared to IM (0.3mg, EpiPen) by Epinephrine pharmacokinetics, pharmacodynamic response and clinical safety.

(https://my.health.gov.il/CliniTrials/Pages/MOH\_2023-07-01\_012776.aspx.)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anaphylaxis Anaphylactic Reaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

To evaluate the comparative bioavailability and pharmacodynamic response between:

A. Epinephrine injection, USP auto-injector 0.3 mg for intramuscular (IM) injection B. FMXIN002 epinephrine microspheres powder for nasal application, 3.6 mg and C. FMXIN002 epinephrine microspheres powder for nasal application, 4 mg and after a single-dose administration to healthy adults

Secondary Objective:

To evaluate the safety and tolerability of the study treatments

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

6 Healthy volunteers, sequence ABC

Three drug administrations to each subject, each administration on a separate day.

treatment order: A B C

Group Type EXPERIMENTAL

A: Epinephrine injection

Intervention Type DRUG

Autoinjector for intramuscular, single-use, 0.3mg

B: FMXIN002 3.6mg

Intervention Type DRUG

Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril

C: FMXIN002 4.0mg

Intervention Type DRUG

Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril

6 Healthy volunteers, sequence BAC

Three drug administrations to each subject, each administration on a separate day.

treatment order: B A C

Group Type EXPERIMENTAL

A: Epinephrine injection

Intervention Type DRUG

Autoinjector for intramuscular, single-use, 0.3mg

B: FMXIN002 3.6mg

Intervention Type DRUG

Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril

C: FMXIN002 4.0mg

Intervention Type DRUG

Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

A: Epinephrine injection

Autoinjector for intramuscular, single-use, 0.3mg

Intervention Type DRUG

B: FMXIN002 3.6mg

Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril

Intervention Type DRUG

C: FMXIN002 4.0mg

Nasus Pharma nasal powder spray 4.0 mg, single use in one nostril

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EpiPen Epinephrine Nasal Product Epinephrine Nasal Product

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\) Non-smoking, male and female subjects from 18 to 55 years of age. 2) BMI ≥18 \< 30 kg/m2. 3) Females may be of childbearing or non-childbearing potential:

* Childbearing potential:

o Physically capable of becoming pregnant, must be willing to use acceptable effective methods of contraception
* Non-childbearing potential:

* Surgically sterile
* Postmenopausal (no menstrual period for at least 12 consecutive months without any other medical cause).

4\) Able to tolerate venipuncture. 5) Be informed of the nature of the study and give written consent prior to any study procedure.

6\) Willing and being able to remain in the clinic for the entire duration of the confinement period.

7\) Have good intravenous access on both arms and hands.

Exclusion Criteria

* 1\) Known history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, ischemic heart disease or Arteriosclerosis or cardiovascular disease, autoimmune disease, or Raynaud Phenomenon and any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.

1. Known history or presence of hypersensitivity or idiosyncratic reaction to epinephrine, sulfite, other excipients of epinephrine auto-injector, or any other drug substances with similar activity.
2. Known history or presence of clinically significant lactose, galactose, or fructose allergy
3. Known history or presence of any food allergy.
4. Presence of nostril or septum piercing.
5. Presence of abnormal nasal anatomy (e.g., polyps, unilateral or bilateral abnormalities of the nares, nasal turbinates, or septum including deviated septum).
6. History of nasal surgery.
7. Presence of a medical condition requiring regular medication (prescription and/or over-the-counter) with systemic absorption other than oral contraceptives.
8. History of drug or alcohol addiction requiring treatment or positive alcohol breath test at check-in.
9. Any acute illness (e.g. cold, acute infection) which is considered significant by the Investigator and that has not resolved within 7 days before the first drug administration.
10. Positive test result for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
11. Positive test result for urine drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone, opiates, phencyclidine, and tricyclic antidepressants) or urine cotinine.
12. Inability to communicate well with the Investigators and staff
13. Non-cooperative or unwilling to sign consent form or unwilling to attend scheduled clinic visits and/or comply with the study protocol.
14. Use of tobacco or nicotine-containing products within 6 months prior to drug administration.
15. Females who:

* Have discontinued or changed the use of implanted, intrauterine, intravaginal, or injected hormonal contraceptives within 6 months prior to drug administration;
* Have discontinued or changed the use of oral or patch hormonal contraceptives within 1 month prior to drug administration;
* Are pregnant (Urine hCG consistent with pregnancy); or
* Are lactating.
16. Donation or loss of whole blood (including clinical trials):

* ≥50 mL and \<500 mL within 30 days prior to drug administration;
* ≥500 mL within 56 days prior to drug administration.
17. Participation in a clinical trial that involved administration of an investigational medicinal product within 30 days prior to drug administration, or recent participation in a clinical investigation that, in the opinion of the Investigator, would jeopardize subject safety or the integrity of the study results.
18. On a special diet within 30 days prior to drug administration (e.g., liquid, protein, raw food diet).
19. Have had a tattoo or body piercing within 30 days prior to drug administration.
20. Have clinically significant findings in vital signs measurements at screening.
21. Systolic blood pressure increase or decrease in value by more than 20 mmHg and/or diastolic blood pressure decrease in value by more than 10 mmHg, from supine or sitting to standing position during orthostatic blood pressure measurement taken at screening.
22. Have clinically significant findings in a 12-lead ECG.
23. Have clinically significant abnormal laboratory values and hemoglobin \<135 g/L for males or \<120 g/L for females at screening.
24. Have significant diseases at screening.
25. Have clinically significant findings from a physical examination.
26. Use of the following drugs within 14 days prior to drug administration:

* Alpha-adrenergic blocking drugs (e.g., phentolamine);
* Anti-arrhythmics;
* Beta-adrenergic blocking drugs (e.g., propranolol);
* Cardiac glycosides;
* Diuretics;
* Drugs having effect on cytochrome P450 (CYP450);
* Enzyme-altering drugs (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine, etc.);
* Enzyme-modifying drugs known to induce/inhibit hepatic drug metabolism;
* Ergot alkaloids;
* Levothyroxine sodium;
* Monoamine oxidase inhibitors;
* Oral or topical corticosteroids;
* Phenylephrine;
* Reserpine-type or clonidine-type antihypertensives;
* Sodium cromoglycate; or
* Tricyclic antidepressants.
27. Use of the following drugs within 7 days prior to drug administration:

* Nasal decongestants;
* Nonsteroidal anti-inflammatory drugs (NSAIDs); or
* Oral or topical antihistamines.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes